Intravenous Immunoglobulin Therapy

What is intravenous immunoglobulin therapy?

Intravenous immunoglobulin therapy (often shortened to IVIG) is a treatment in which purified antibodies are given directly into a vein through a drip. Antibodies, also called immunoglobulins, are proteins that the immune system normally makes to recognize and fight infection. The immunoglobulin used for IVIG is collected from the plasma (the liquid part of blood) of thousands of healthy screened donors, pooled together, purified and treated to inactivate viruses before it is prepared as a medicine.

Doctors use intravenous immunoglobulin therapy for two broad purposes. The first is replacement: people whose bodies do not make enough working antibodies, a group of conditions known as primary or secondary immunodeficiency, receive regular infusions so that they have the antibodies they need to help prevent infections. The second is immune modulation: in certain autoimmune and inflammatory conditions, where the immune system mistakenly attacks the body’s own tissues, high doses of immunoglobulin appear to calm or redirect that harmful immune activity. Exactly how this works is not fully understood, but several mechanisms are thought to act at the same time.

Conditions in which intravenous immunoglobulin therapy is commonly used include:

• Primary immunodeficiency disorders, such as common variable immunodeficiency (a condition in which the body produces too few effective antibodies).
• Guillain-Barré syndrome, a sudden immune attack on the peripheral nerves that causes weakness and sometimes paralysis.
• Chronic inflammatory demyelinating polyneuropathy (CIDP), a longer-lasting nerve condition in which the protective coating of nerves is damaged.
• Immune thrombocytopenia (ITP), in which the immune system destroys platelets, the blood cells that help clotting.
• Kawasaki disease, an inflammatory illness of childhood that can affect blood vessels of the heart.
• Myasthenia gravis, a condition causing muscle weakness, often during a severe flare.
• Some other neurological, blood, skin and rheumatological conditions, usually when standard treatments have not worked or cannot be used.

Because many of these conditions affect the nervous system, IVIG is frequently coordinated through a hospital’s neurology department together with hematology, immunology and infusion nursing teams.

Who is a candidate: who needs intravenous immunoglobulin therapy

The decision about who needs intravenous immunoglobulin therapy is made by a specialist after reviewing the diagnosis, the severity of the condition and the alternatives. In general, a person may be considered a candidate when:

• Blood tests confirm a lasting shortage of antibodies with repeated or serious infections.
• A recognized autoimmune condition, such as Guillain-Barré syndrome or CIDP, is causing significant weakness or disability and IVIG is an accepted treatment option.
• Other treatments, for example steroids or other immune-suppressing medicines, have not worked, have caused unacceptable side effects, or are unsafe for that person.
• A rapid effect is needed, for instance to raise a dangerously low platelet count before surgery.

Intravenous immunoglobulin therapy is not suitable for everyone. Your doctor may advise against it, or take extra precautions, in the following situations:

• A previous severe allergic reaction to immunoglobulin products.
• Selective IgA deficiency with antibodies against IgA (IgA is one type of immunoglobulin), because this raises the risk of a serious reaction with some products.
• Significant kidney disease, since some immunoglobulin products can strain the kidneys.
• A history of blood clots, heart failure or very thick blood, because IVIG can increase blood thickness and the risk of clotting.
• Conditions for which the evidence of benefit is weak or absent; IVIG is a limited resource made from donated plasma, so it is generally reserved for conditions where it is expected to help.

Pregnancy is not an automatic barrier, and IVIG is sometimes used during pregnancy for specific conditions, but this is always weighed individually.

How the intravenous immunoglobulin therapy procedure works

The intravenous immunoglobulin therapy procedure is an infusion, not an operation. No anesthesia is required. Below is what typically happens before, during and after a session.

Before the infusion. A nurse checks your temperature, blood pressure, pulse and breathing. You may be asked about recent illness, allergies and how you tolerated previous infusions. In many cases you will be given pre-medication such as acetaminophen (paracetamol) or an antihistamine to reduce the chance of a reaction, and you will be encouraged to drink fluids. A small plastic tube called a cannula is placed into a vein, usually in the hand or arm. Some people who need long-term treatment have a port or other central venous access device inserted separately.

During the infusion. The immunoglobulin solution is delivered slowly through the cannula using a pump. The infusion usually starts at a slow rate and is gradually increased if you are tolerating it well. Nurses monitor your vital signs at regular intervals and watch for signs of a reaction such as chills, headache, flushing or a rash. If a reaction occurs, the infusion is slowed or paused and treated, and can often be restarted at a lower rate. A single session commonly lasts between two and six hours depending on the dose, your body weight and the product used.

After the infusion. The cannula is removed and a small dressing is applied. You will usually be observed for a short period before going home. Most people can leave the infusion unit the same day, although those receiving high-dose treatment for a severe acute illness are often already admitted to the hospital.

Treatment schedules vary. For immunodeficiency, infusions are commonly repeated every three to four weeks on an ongoing basis. For autoimmune conditions, a high dose is often divided over two to five consecutive days, with further courses depending on how the condition responds.

Preparation for intravenous immunoglobulin therapy

Careful preparation helps reduce side effects and makes the infusion day easier. Your care team will give instructions specific to you, but preparation typically includes:

• Blood tests. Before the first course, doctors usually check kidney function, a full blood count and, in some cases, immunoglobulin levels. A baseline blood sample may also be stored because IVIG contains donor antibodies that can temporarily interfere with certain blood tests.
• Medication review. Bring a list of all medicines and supplements. Tell the team about diuretics (water tablets), blood thinners and any recent vaccinations, because live vaccines given close to IVIG may be less effective.
• Hydration. Drinking plenty of water in the day before and on the day of treatment is often recommended, unless your doctor has told you to restrict fluids.
• Eat normally. Fasting is not usually required. A light meal before the infusion is generally fine.
• Comfort. Sessions are long, so wear loose clothing with sleeves that roll up easily, and bring something to read or watch. Many units allow a companion.
• Report illness. If you have a fever or an active infection on the day, tell the team beforehand; the infusion may be postponed.

Recovery and aftercare: intravenous immunoglobulin therapy recovery time

Because there is no incision or anesthesia, intravenous immunoglobulin therapy recovery time is usually short. Many patients feel tired, achy or have a mild headache for the rest of the day and sometimes for one to two days afterward, particularly after the first infusion or a high-dose course. Typically these symptoms settle on their own with rest, fluids and simple pain relief agreed with your doctor.

Practical aftercare often includes:

• Continuing to drink fluids for a day or two after treatment.
• Resting on the evening of the infusion and avoiding strenuous activity until you feel back to normal.
• Keeping the cannula site clean and watching for redness, swelling or pain.
• Arranging transport home if you feel unwell, drowsy or have taken an antihistamine.
• Keeping a simple diary of any side effects to discuss at the next visit; this helps the team adjust the rate, the product or the pre-medication.

Recovery from the underlying condition is a separate matter. In immunodeficiency, the aim is prevention, so you may not notice an immediate change beyond fewer infections over time. In acute neurological conditions such as Guillain-Barré syndrome, improvement in strength often begins over days to weeks, but rehabilitation with physical therapy may continue for months. Your specialist will explain what a realistic timeline looks like for your situation.

Risks and side effects: intravenous immunoglobulin therapy risks and benefits

Weighing intravenous immunoglobulin therapy risks and benefits is a shared decision between you and your doctor. IVIG has been used for decades and is generally considered well tolerated, but it is a blood-derived product given in large volumes, so side effects can occur.

Common, usually mild side effects often appear during or shortly after the infusion and include:

• Headache, sometimes lasting into the next day.
• Chills, fever or flushing.
• Muscle or joint aches and fatigue.
• Nausea.
• Mild changes in blood pressure or heart rate.
• Skin rash or itching.

These reactions are often related to the infusion speed and are typically managed by slowing the drip, giving fluids and using pre-medication at future sessions.

Less common but more serious risks include:

• Severe allergic (anaphylactic) reaction, which is rare but requires immediate treatment; infusion units are equipped for this.
• Aseptic meningitis, an inflammation of the lining of the brain not caused by infection, which causes severe headache, neck stiffness and light sensitivity, usually within a day or two, and generally resolves.
• Blood clots, including deep vein thrombosis, stroke or heart attack, especially in people who are older, immobile, dehydrated or have existing risk factors.
• Kidney injury, more likely with certain older sucrose-containing products and in people with existing kidney disease or dehydration.
• Hemolysis, a breakdown of red blood cells that can cause anemia, more often with high doses in people with certain blood groups.
• Fluid overload in people with heart or kidney problems, because of the volume infused.
• Transfusion-related acute lung injury, a rare breathing complication.

Because the product comes from human plasma, there is a theoretical risk of transmitting infection. Modern donor screening and manufacturing steps that inactivate and remove viruses have made this risk extremely low, but it cannot be described as zero.

The benefits depend on the condition. For people with antibody deficiency, regular IVIG is a well-established way to reduce serious bacterial infections and protect the lungs from long-term damage. For Guillain-Barré syndrome and CIDP, IVIG is one of the main proven treatments and can shorten recovery or reduce disability. For ITP, it can raise platelet counts quickly when this is urgently needed. Your doctor will explain what benefit is realistically expected in your case.

Results and outlook

The results of intravenous immunoglobulin therapy vary considerably by diagnosis, so it is important not to generalize from one condition to another.

In primary immunodeficiency, regular replacement therapy is usually lifelong. Studies and clinical experience consistently show that people who maintain adequate immunoglobulin levels have fewer and less severe infections and better long-term lung health than those who go untreated. Dosing is adjusted over time based on blood levels and how often infections occur.

In Guillain-Barré syndrome, IVIG has been shown in clinical trials to speed recovery when given early, and it is considered as effective as plasma exchange, the main alternative. Many people recover well over months, although some are left with residual weakness or fatigue, and the outlook depends on the severity of the initial illness.

In CIDP, a large proportion of patients improve with IVIG, but many need repeated courses to maintain the benefit, and the treatment interval is tailored individually. Some people eventually move to home-based or subcutaneous (under the skin) immunoglobulin, which is a related treatment given by a different route.

In ITP, the rise in platelets is often rapid but temporary, typically lasting a few weeks, so IVIG is generally used as a bridge rather than a long-term solution.

For other conditions where IVIG is used off-label (outside its formally approved indications), the evidence is more limited and responses are less predictable. In these cases doctors usually set clear goals and a time frame for judging whether the treatment is worth continuing.

Cost considerations

Intravenous immunoglobulin therapy is generally an expensive treatment, and the total cost is influenced by several factors rather than a single fee. The main drivers include:

• The dose and number of infusions. IVIG is dosed by body weight, and high-dose immunomodulatory courses use far more product than replacement doses. Ongoing treatment repeated every few weeks adds up over time.
• The immunoglobulin product itself. The manufacturing process, which involves plasma collection from many donors and multiple purification and safety steps, makes the medicine the largest part of the cost in most cases.
• Setting of care. Infusions given in an outpatient infusion unit are usually less costly than treatment during a hospital admission, which includes bed charges and nursing time.
• Venous access devices. If a port or other long-term line is needed, its insertion and maintenance are additional.
• Monitoring and follow-up. Blood tests, specialist consultations and management of any side effects contribute to the overall expense.
• Pre-medication and supportive care. These are usually a small part of the total.

Insurance coverage and public health system funding vary widely between countries and between diagnoses, and approval often depends on whether the condition is a recognized indication. Patients are usually advised to ask the treating hospital for a written estimate and to clarify coverage before starting a long-term course. Acibadem infusion services provide such estimates on request through the relevant department.

Frequently asked questions

What is intravenous immunoglobulin therapy used for most often?

It is most often used to replace missing antibodies in people with immunodeficiency, and to calm the immune system in autoimmune conditions such as Guillain-Barré syndrome, CIDP, immune thrombocytopenia, Kawasaki disease and severe myasthenia gravis. Use in other conditions is generally reserved for situations where standard treatments have failed or are unsuitable, and the decision is made by a specialist.

How long does the intravenous immunoglobulin therapy procedure take?

A single infusion typically takes two to six hours, depending on the dose, your weight, the product and how quickly you tolerate the drip. First infusions are usually run more slowly. High-dose courses for autoimmune conditions are often spread over two to five consecutive days, while replacement therapy is usually a single session every three to four weeks.

What is the usual intravenous immunoglobulin therapy recovery time?

Most people can return to normal daily activities the following day. Tiredness, headache or muscle aches may last one to two days, particularly after the first treatment or a high-dose course. Recovery from the underlying condition, such as regaining strength after a nerve disorder, follows its own timeline and may take weeks to months.

Who needs intravenous immunoglobulin therapy on a long-term basis?

People with primary immunodeficiency usually need lifelong replacement, and some people with CIDP or other chronic autoimmune conditions need repeated courses to maintain improvement. For acute conditions such as Guillain-Barré syndrome or an ITP flare, a single course may be enough. Your specialist reviews the need for ongoing treatment at regular intervals.

What are the main intravenous immunoglobulin therapy risks and benefits I should weigh?

The most common side effects are headache, chills, aches and fatigue, which are usually mild and manageable. Rarer risks include severe allergic reaction, blood clots, kidney injury, aseptic meningitis and red blood cell breakdown. Benefits range from fewer infections in immunodeficiency to faster recovery in certain nerve disorders. Your doctor will weigh these against your personal risk factors and alternatives.

Can intravenous immunoglobulin therapy be given at home?

In some countries and for some stable patients, IVIG can be given at home by a trained nurse once the person has tolerated several infusions in the hospital. A related treatment, subcutaneous immunoglobulin, is given under the skin and is often self-administered at home. Whether these options are available depends on your condition, your health system and your doctor’s assessment.

Does intravenous immunoglobulin therapy affect vaccines?

Yes, it can. Because IVIG contains donor antibodies, it may reduce the response to live vaccines such as measles, mumps and rubella or varicella for several months. Non-live vaccines are generally less affected. Tell your doctor about any planned vaccinations so that timing can be adjusted where appropriate.

When to see a doctor

You should be assessed by a specialist if you have repeated or unusually severe infections, especially of the lungs, sinuses or ears, or if you develop progressive weakness, numbness or tingling in the arms and legs, unexplained easy bruising or bleeding, or a diagnosed autoimmune condition that is not responding to current treatment. These situations do not mean you need IVIG, but they warrant a proper evaluation by an immunologist, neurologist or hematologist who can decide whether it is appropriate.

After an infusion, seek urgent medical attention if you notice any of the following red flags:

• Difficulty breathing, wheezing, swelling of the face, lips or throat, or a widespread rash, which may indicate a severe allergic reaction.
• Severe headache with neck stiffness, sensitivity to light, or vomiting, which may suggest aseptic meningitis.
• Chest pain, sudden shortness of breath, coughing up blood, or a painful, swollen, warm leg, which may indicate a blood clot.
• Sudden weakness on one side of the body, facial drooping, confusion or trouble speaking, which are possible signs of stroke.
• Passing much less urine than usual, dark urine, or swelling of the legs, which may point to kidney problems or fluid overload.
• Yellowing of the skin or eyes, unusual paleness or extreme tiredness, which may suggest red blood cell breakdown.
• Fever above 38°C (100.4°F) that persists, or redness, pain and pus at the cannula or port site.

If you experience milder but persistent side effects, or if you feel the treatment is not helping, discuss this at your next appointment so that your care team can review the dose, the infusion rate or the treatment plan.